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Expression and Function of PML-RARA in the
Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
Lukas D. Wartman1., John S. Welch1., Geoffrey L. Uy1, Jeffery M. Klco2, Tamara Lamprecht1,
Nobish Varghese2, Rakesh Nagarajan2, Timothy J. Ley1*
1 Section of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America,
2 Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract
Because PML-RARA-induced acute promyelocytic leukemia (APL) is a morphologically differentiated leukemia, many groups
have speculated about whether its leukemic cell of origin is a committed myeloid precursor (e.g. a promyelocyte) versus an
hematopoietic stem/progenitor cell (HSPC). We originally targeted PML-RARA expression with CTSG regulatory elements,
based on the early observation that this gene was maximally expressed in cells with promyelocyte morphology. Here, we
show that both Ctsg, and PML-RARA targeted to the Ctsg locus (in Ctsg-PML-RARA mice), are expressed in the purified KLS
cells of these mice (KLS = Kit+Lin2Sca+, which are highly enriched for HSPCs), and this expression results in biological effects
in multi-lineage competitive repopulation assays. Further, we demonstrate the transcriptional consequences of PML-RARA
expression in Ctsg-PML-RARA mice in early myeloid development in other myeloid progenitor compartments [common
myeloid progenitors (CMPs) and granulocyte/monocyte progenitors (GMPs)], which have a distinct gene expression
signature compared to wild-type (WT) mice. Although PML-RARA is indeed expressed at high levels in the promyelocytes of
Ctsg-PML-RARA mice and alters the transcriptional signature of these cells, it does not induce their self-renewal. In sum,
these results demonstrate that in the Ctsg-PML-RARA mouse model of APL, PML-RARA is expressed in and affects the
function of multipotent progenitor cells. Finally, since PML/Pml is normally expressed in the HSPCs of both humans and
mice, and since some human APL samples contain TCR rearrangements and express T lineage genes, we suggest that the
very early hematopoietic expression of PML-RARA in this mouse model may closely mimic the physiologic expression
pattern of PML-RARA in human APL patients.
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RARA to the promyelocyte compartment [6,7,8,9,10]. However,
human PML and murine Pml are expressed in early CD34+
hematopoietic progenitor cells, and human PML-RARA expression
may not be limited to committed myeloid progenitors and
promyelocytes [11,12].
Several studies have suggested that in APL, the leukemic cell of
origin must be a committed myeloid progenitor [10]. First,
Turhan et al. did not observe PML-RARA expression in flowsorted CD34+/CD382 cells (a cell population enriched for less
mature hematopoietic progenitors, including stem cells), but did
detect PML-RARA expression in CD34+/CD38+ cells (a population enriched for more mature hematopoietic progenitors,
including early myeloid committed progenitors) from two APL
patients, using semi-quantitative RT-PCR [7]. Secondly, Bonnet
and Dick observed engraftment of CD34+/CD382 AML cells into
NOD/SCID mice, but no engraftment of similarly sorted CD34+/
CD382 cells from APL patients, suggesting that these were not the

Introduction
The fusion gene PML-RARA is produced by t(15;17)(q22;q21),
and is found only in the hematopoietic cells of patients with acute
promyelocytic leukemia (APL). When PML-RARA is expressed in
mice using regulatory elements from the human or mouse
cathepsin G gene (CTSG/Ctsg) or the human S100A8 (MRP8)
promoter/enhancer, it can initiate APL; when RARA or PMLRARA are expressed in mouse bone marrow cells via retroviral
transduction, both can decrease myeloid maturation and increase
self-renewal [1,2,3,4]. Human APL is associated with differentiation arrest at the promyelocyte stage; in mouse models of the
disease, this maturation arrest is less pronounced and varies
between models, for reasons that are not yet clear. However, the
disease is always myeloid-restricted [5]. Because murine models of
APL were designed to target PML-RARA expression to myeloidrestricted cells, we and others have suggested that myeloidrestricted disease might result from targeted expression of PMLPLOS ONE | www.plosone.org
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initiating cells for this subtype of AML [13]. Many authors have
suggested that mouse models of APL support this hypothesis, since
expression of PML-RARA under the control of Ctsg or MRP-8
regulatory elements has led to myeloid leukemia [8,9,10,14].
However, Chapiro et al. recently reported expression of T-lineage
transcripts and TCR rearrangements in 60% of hypogranular
t(15;17) APL cases, suggesting the translocation may affect HSPCs
with the capacity to differentiate into both myeloid and lymphoid
lineages [14]. In addition, APL cells often do not express CD34 on
the cell surface, but do often express atypical lymphoid linage
markers (CD56, CD19, or CD2), again suggesting that PMLRARA may initiate disease (in human patients) within a multipotent progenitor compartment [15].
In this study, we use state-of-the-art flow-sorting, mRNA
amplification, and expression profiling strategies to carefully
define the timing of activation of Ctsg and PML-RARA during
early hematopoietic development in Ctsg-PML-RARA mice. We
found that Ctsg mRNA is expressed not only in the KLS (Kit+/
Lin2/Sca+) compartment, but also in SLAM cells (CD150+/
CD412/CD482 KLS), which are even more primitive. We
observed striking changes in the gene expression profile of flowsorted common myeloid progenitors (CMPs) and granulocyte/
monocyte progenitors (GMPs) derived from Ctsg-PML-RARA mice,
which suggests that PML-RARA has important transcriptional
consequences in early myeloid progenitor cells. We extend these
findings with functional validation of PML-RARA effects on
lymphoid and erythroid lineages, which confirm that PML-RARA
is expressed (and functional) at a very early stage in the
hematopoietic development of Ctsg-PML-RARA mice. We observed that in flow-sorted Ctsg-PML-RARA promyelocytes, PMLRARA expression does result in significant gene expression changes
but does not result in distinct gene expression signature, nor does it
promote self-renewal. These results change our understanding of
the cellular compartments in which PML-RARA initiates leukemia
in the Ctsg-PML-RARA mouse model of APL.

Figure 1. Expression of Ctsg in flow-sorted bone marrow cells
and mouse leukemia samples. Expression profile in indicated WT
and Ctsg-PML-RARA (labeled mCG-PR) flow-sorted bone marrow cells
and 15 Ctsg-PML-RARA leukemia samples (labeled Mouse APL) using
Nugen amplified mRNA and Affymetrix Mouse Exon 1.0ST arrays. We
plotted Ctsg expression for probeset 5542324. Note the absence of Ctsg
mRNA in Ctsg deficient cells (labeled Ctsg KO). There were no
statistically significant differences in Ctsg expression between the same
cell populations, when comparing WT and Ctsg-PML-RARA samples
(using two-tailed t test, p-value cutoff 0.05). Comparing the levels of
Ctsg expression between the Ctsg-PML-RARA samples using a two-tailed
t test, the p-value for SLAM vs. KLS = 0.11, KLS vs. CMPs = 0.00026, CMPs
vs. GMPs = 0.022, GMPs vs. MEPs 2.461028, MEPs vs. Pros 2.661027,
GMPs vs. Pros = 0.027, Pros vs. PMNs = 2.461026.
doi:10.1371/journal.pone.0046529.g001

Using very sensitive quantitative RT-PCR to further investigate
the timing of Ctsg activation, we found that Ctsg mRNA could be
detected not only in the KLS compartment but also in SLAM cells
(Figure S2A). However, we could not reliably detect PML-RARA
expression in SLAM cells, demonstrating that PML-RARA
expression is at or below the level of detection by RT-PCR
(Figure S2B and S2C). We have previously shown that the
expression of the PML-RARA transgene driven from the Ctsg locus
is much lower than that of endogenous Ctsg from a WT locus, so
this result is consistent with those findings [1,2]. As expected,
PML-RARA mRNA was not detected in bone marrow cells from
WT littermate controls [8].
We noted that Ly6g (Gr-1) expression was limited to promyelocytes and neutrophils, and that Kit and Flt3 expression declined
during myeloid maturation, as expected (Supplemental Figures
S3A, S3B, and S3C). Promyelocytes had relatively low but
detectable expression of Cd34 with an average expression intensity
of 785.912672.575 in Ctsg-PML-RARA promyelocytes (n = 3) and
467.2556189.475 in WT promyelocytes (n = 6) with much higher
Cd34 expression in the earlier myeloid compartments, CMPs and
GMPs, as expected (Figure S3D). Importantly, we detected no
expression of Ly6g in SLAM and KLS cells, demonstrating
efficient negative selection of differentiated myeloid cells within
these populations: all probes had signal intensity ,100, whereas
signal intensity ,200 represents experimental ‘noise’ on this
platform (Figure S3A).
We confirmed the purification of the sorted compartments by
plotting the expression of myeloid genes that are known to be
developmentally-regulated: myeloperoxidase (Mpo), elastase (Ela2),

Results
Expression of PML-RARA and the genes used to direct
expression in APL mouse models
We analyzed the expression profiles of flow-sorted SLAM cells
(cKit+Lin2Sca+CD150+CD412CD482), KLS cells (cKit+Lin2Sca+), CMPs (Lin2Sca-12cKit+CD34+FccRII/IIIlo), GMPs
(Lin2Sca-12cKit+CD34+FccRII/IIIhi), megakaryocyte-erythrocyte progenitors (MEPs; Lin2Sca-12cKit+CD342FccRII/IIIlo),
‘‘promyelocytes’’/early
myeloid
cells
(Ly6gintSCint
2
2
2
C B220 CD115 Ter119 ), and neutrophils (Ly6g+SCChighB2202CD1152Ter1192) from 2–6 individual Ctsg-PMLRARA or WT mice (Figure S1).
In our mouse model of APL, PML-RARA is inserted into the 59
untranslated region of Ctsg, and the Ctsg locus therefore regulates
its expression [2]. To begin to define when PML-RARA expression
is activated in this model during hematopoietic development, we
first examined the expression of the Ctsg gene in all the
compartments listed above, using young WT and Ctsg-PML-RARA
mice (Figure 1). Ctsg expression is not consistently detected in the
SLAM compartment by exon array. However, KLS cells express
detectable amounts of Ctsg mRNA by exon array, and this
expression is absent in KLS cells derived from Ctsg deficient mice
(proving the specificity of the probesets for Ctsg transcripts). Ctsg
expression increases massively in the CMP compartment; the high
level of expression persists in the GMP compartment and in
promyelocytes, and declines in neutrophils. Ctsg is minimally
expressed in the MEP compartment.
PLOS ONE | www.plosone.org
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peaking in neutrophils, rather than promyelocytes (Figure 3A and
3B). In contrast, S100A8 is highly expressed in human AML cells
and in flow-sorted CD34+ cells, with massive up-regulation at the
promyelocyte stage (Figure 3C). High expression of S100a8 was
also seen in murine hematopoietic cells, although dynamic
regulation during promyelocyte maturation was absent
(Figure 3D). The expression pattern of these loci contrasts with
that of human PML and murine Pml, which are expressed at much
lower levels, and which exhibit little or no dynamic regulation
during myeloid maturation (Figure 3E and 3F).

and proteinase3 (Prtn3) are expressed early in myeloid development in primary granules; lactoferrin (Ltf) is expressed later in
secondary granules; and matrix metallopeptidase 9 (Mmp9) found
in tertiary granules is a marker of mature neutrophils (Figure S4A–
E). [9,16,17]. In addition, we show that the mature myeloid
markers formyl peptide receptor 1 (Fpr1) and lysozyme-2 (Lyz2) are
appropriately expressed in our sorted cell populations (Figure S4F
and S4G) [18]. The expression data from 11 developmentallyregulated myeloid genes was used to construct a supervised
heatmap (by z-score) which clearly illustrates the expected levels of
gene expression at the appropriate stage of myeloid development
for our sorted cell populations (Figure 2).
Regulatory elements from other ‘‘myeloid-restricted’’ genes
have also been used to generate mouse models of APL. One
transgenic strategy (using the S100A8 (MRP8) 59 flanking region)
resulted in myeloid leukemia, while two others (using Fes and Itgam
(CD11b) promoters) did not [3,19,20]. Using data from the same
expression arrays, we found that Fes and Itgam are both expressed
at much lower levels in KLS cells than Ctsg, with expression

Effects of Ctsg-PML-RARA in multiple hematopoietic
compartments
To determine whether PML-RARA expression from the Ctsg
locus results in biological effects on multipotent hematopoietic
cells, we used four independent approaches. First, we used
transcriptional profiling using exon arrays of SLAM, KLS,
MEP, CMP, GMP, promyelocyte and mature neutrophil populations from Ctsg-PML-RARA and WT mice. We performed

Figure 2. A supervised heatmap of 11 developmentally-regulated myeloid genes. Using the expression data from the Affymetirix Mouse
Exon 1.0ST arrays, we created a supervised heatmap with SPOTFIRE using z-score averaging of the probeset with the highest average expression for
each of 11 developmentally-regulated myeloid genes across all of our flow-sorted bone marrow cell samples. The legend is shown below the
heatmap with downregulated genes in green and upregulated genes in red.
doi:10.1371/journal.pone.0046529.g002

PLOS ONE | www.plosone.org
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Figure 3. Expression of genes used to target PML-RARA expression in mice. Expression data for the indicated genes in flow-sorted bone
marrow cells using murine Affymetrix Exon 1.0ST arrays or Human Genome U133 Plus 2.0 arrays. Each panel is a highly representative probe on the
array. A. cFes (probeset 4758608). B. Itgam (CD11b, probeset 4782002). C. S100A8 (MRP8, probeset 202917). D. S100a8 (Mrp8, probeset 5010279). E.
PML (probeset 235508). F. Pml (probeset 4885841). We have previously published the expression profile of PML in AML and human hematopoietic
cells [11]. Panel E includes an additional 86 AML cases of AML and data from a second representative probe.
doi:10.1371/journal.pone.0046529.g003
PLOS ONE | www.plosone.org
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unsupervised hierarchical clustering analyses to assess the global
effects of PML-RARA expression on gene expression in KLS and
SLAM cells. We observed that KLS (but not SLAM) samples
segregated by genotype in an unsupervised clustering analysis,
suggesting that expression of PML-RARA within the KLS
compartment significantly alters the expression of a specific set
of genes (Figure S5A). Although many genes were significantly
dysregulated in the comparison between WT and Ctsg-PML-RARA
promyelocytes, this cell population did not cluster by genotype in
an unsupervised analysis (Figure S5B).
To assess the downstream consequences of PML-RARA expression in early myeloid progenitors, we purified CMPs and GMPs
for expression analysis. These populations segregated by CtsgPML-RARA genotype in unsupervised hierarchical clustering,
whereas MEPs did not cluster by genotype (Figure S6). To
ascertain significant differences in specific gene expression between
the Ctsg-PML-RARA and WT samples, we performed ANOVA
and Significance of Microarrays (SAM) analysis to define
significantly dysregulated genes in each subset (Tables S1, S2,
S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, 13 and Data S1). In the
KLS comparison, one of the most significantly dysregulated genes
by ANOVA was Notch1 (Table S2), which is relevant for the recent
finding of activated Notch1 signaling in both human and murine
APL pathogenesis (Grieselhuber NR et al., submitted). Unexpectedly, one of the most significantly dysregulated genes within the
CMP and GMP compartments was Cadherin 1 (Cdh1), a tumor
suppressor in epithelial cancers, which was strikingly up-regulated
in both the CMP and GMP compartments of Ctsg-PML-RARA
mice (Table S7) [21]. We also found that cyclin H (Ccnh) expression
is down-regulated in the CMP compartment of Ctsg-PML-RARA
mice (Table S3): cyclin H has been previously shown to be part of
a complex that phosphorylates the AF-2 domain of RARA,
leading to the downstream activation of retinoic acid responsive
genes [22].
To highlight the changes in gene expression in the CMP and
GMP populations, we performed a supervised clustering analysis
of the twenty-two genes that were significantly dysregulated
(unadjusted p value,0.001, fold change $2) in both the CMP and
GMP ANOVA results (the supervised heatmap was created by
plotting the relative expression of each of these genes to each
other) (Figure 4). Interestingly, this gene expression signature is not
present in earlier cell populations (KLS or SLAM), in more mature
myeloid cells (promyelocytes and neutrophils), nor the leukemic
cells from the Ctsg-PML-RARA mice. Also, there is no concordant
overlap between genes dysregulated in the CMP or GMP
compartments versus promyelocytes.
To further validate the changes in gene expression in the CMP
and GMP compartments, we performed supervised clustering
analyses of all the significantly dysregulated genes by ANOVA
(unadjusted p value,0.001, fold change $2) from the GMP and
CMP compartments individually (these heatmaps were created by
traditional z-score scaling). As expected, the clustering with genes
dysregulated in either the CMP or GMP compartment segregated
both the GMP and CMP populations, but not the MEP
populations, by genotype (Figure S7A and S7B). Thus, the
expression of PML-RARA in Ctsg-PML-RARA mice has clear
transcriptional consequences that occur early in myeloid development and are specific for the CMP and GMP cell populations.
These transcriptional changes, in turn, may influence the gene
expression profile of more mature myeloid cells, just as gene
expression changes driven by the presence of PML-RARA
expression in earlier hematopoietic precursors may shape the
distinct expression signature seen in the CMP and GMP
compartments.
PLOS ONE | www.plosone.org

Secondly, we assessed the function of Ctsg-PML-RARA bone
marrow cells after competitive transplantation. We transplanted
total bone marrow from healthy 6-week-old (i.e. non-leukemic)
Ctsg-PML-RARA mice (CD45.2+) at ratios of 1:9, 1:1, and 9:1 with
competitor Ly5.1/Ly5.2 bone marrow (CD45.1+/CD45.2+) into
Ly5.1 recipients (CD45.1+). Peripheral blood was assessed at 6
weeks, 3 months, and 6 months post-transplant. Four mice
developed leukemia between 3 and 6 months, and could not be
analyzed further. As expected, we noted a consistent expansion of
Ctsg-PML-RARA+ cells within the Ly6g+ (myeloid) compartment at
all time points tested (Figure 5A). However, we also observed an
expansion of Ctsg-PML-RARA+ cells within the CD3+ and B220+
compartments at 3 and 6 months (Figure 5A).
Thirdly, we examined the function of erythroid progenitors
derived from Ctsg-PML-RARA mice. Total Ctsg-PML-RARA bone
marrow cells contained significantly more BFU-Es than wild-type
littermate controls (Figure 5B). There was no difference in the
percentage of mature erythroid cells (Ter119+CD71high, 24%68%
vs 37%618%, p = 0.1; Figure S8A) in these colonies, although
Ctsg-PML-RARA BFU-E colonies contained more immature
erythroid cells (cKit+CD71dim, 12.7%62.3% vs 7%63.5%,
p = 0.007; Figure 5C) and more myelomonocytic/monocytic cells
(CD11b+, 32%64.4% vs 21%69.6%, p = 0.02; Figure S8B). The
lack of transcriptional changes in flow sorted MEP cells (Tables S5
and S12) may be accounted for by differences between the
immunophenotypically defined MEPs and the physiologically
defined colony forming cell (which may be less mature than MEP
cells). Evaluation of a large cohort of mice (n = 19 Ctsg-PML-RARA
and 15 wild-type littermate controls) revealed normal hemoglobin
levels and red cell size in all mice (Figure S8C and S8D),
suggesting that PML-RARA-dependent effects on BFU-Es are not
associated with a loss of erythroid homeostasis in vivo. These results
parallel our previous finding that myeloid CFUs are increased in
healthy pre-leukemic Ctsg-PML-RARA mice, but do not lead
directly to increased numbers of circulating neutrophils [23,24].
Finally, we asked whether promyelocyte self-renewal was altered
in Ctsg-PML-RARA mice. As expected, we observed that KLS cells
from Ctsg-PML-RARA mice contained increased numbers of CFUs
compared with purified promyelocytes (Figure 6B and 6C). We
also observed a trend toward increased numbers of CFUs in CtsgPML-RARA KLS cells compared with wild-type KLS cells. Serial
re-plating was detected with Ctsg-PML-RARA KLS cells, as
expected, but was not found with Ctsg-PML-RARA promyelocytes
(Figure 6C). Transplantation of pools of donor KLS cells (3,000
cells per sub-lethally irradiated Ly5.1 recipient) from either WT or
Ctsg-PML-RARA mice led to multi-lineage engraftment, as
expected (Figure 6D and Figure S9A–C). In contrast, transplantation of 50,000 purified promyelocytes led to trace engraftment
(,1% of bone marrow leukocytes) regardless of genotype, which
was not myeloid restricted (Figure 6D–E and Figure S9D–F).

Discussion
The fusion protein PML-RARA is associated exclusively with
myeloid leukemia in both humans and mice (unlike BCR-ABL and
MLL fusion proteins, which can lead to myeloid or lymphoid
leukemias) [2,3,5,25,26,27]. There has therefore been much
speculation regarding whether the leukemic cell of origin is a
committed progenitor (e.g. a promyelocyte) or multipotent
progenitor [5,6,7,8,10,14,28]. The data presented here show that
when PML-RARA is inserted into the murine Ctsg locus, it begins to
be expressed in KLS cells, where it alters myeloid, lymphoid, and
erythroid hematopoiesis (biologically confirming its activity in
multipotent cells). It is massively upregulated in CMP and GMP
5
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Figure 4. A supervised heatmap of the 22 genes significantly dysregulated in both the CMP and GMP compartments. We created a
supervised clustering using SPOTFIRE of the 22 genes that were significantly dysregulated (unadjusted p value,0.001, fold change $2) in both the
CMP and GMP ANOVA results comparing WT vs. Ctsg-PML-RARA samples. The supervised heatmap was created by plotting the relative expression of
each of these genes to each other as a relative percentage, rather than z-score averaging, since the differences in expression levels between some
genes was large, and z-score averaging inappropriately highlighted the genes with the highest expression levels. The legend is shown below the
heatmap, with minimally expressed genes in green, and highly expressed genes in red.
doi:10.1371/journal.pone.0046529.g004

cells, where it significantly alters the expression of a number of
genes. In contrast, PML-RARA expression in promyelocytes is not
associated with a striking change in gene expression or inappropriate self-renewal. The studies described here define the
hematopoietic compartments that are initially exposed to (and
perturbed by) PML-RARA in healthy, pre-leukemic Ctsg-PMLRARA mice; the immunophenotype and cytomorphology of
leukemia initiating cells within the subsequent leukemias have
been defined elsewhere, and are not addressed in this analysis
[8,9].
One of the important arguments used to support a committed
progenitor as the leukemic cell of origin has been the successful
generation of leukemia using CTSG, Ctsg, and S100A8 loci, which
were thought to target PML-RARA to the promyelocyte compartment [10]. However, we and others have now found that in CtsgPML-RARA mice, PML-RARA is consistently expressed in cells
within the KLS compartment, [8], and is strikingly upregulated in
PLOS ONE | www.plosone.org

committed myeloid progenitor cells. We have therefore reevaluated the expression patterns of the genes used to direct PML-RARA
expression in mice: PML-RARA directed from the CTSG, Ctsg and
S100A8 (MRP8) loci cause APL; expression directed by regulatory
elements from the cFes and Itgam (CD11b) loci do not
[1,2,3,19,20]. Ctsg, CTSG, S100a8, and S100A8 are all expressed
in multipotent progenitor compartments, while cFes and Itgam
display low to absent levels of expression in KLS cells, with
maximal expression in neutrophils. This suggests that APL
development may require PML-RARA expression in an early
hematopoietic compartment, and that induction of expression at
the promyelocyte stage is insufficient to initiate leukemia, perhaps
because PML-RARA cannot reverse the commitment of terminally differentiated neutrophils to die.
Other authors have evaluated the cell-specific effects of PMLRARA and MLL fusion transcripts using viral transduction
[4,29,30,31]. We have focused our analysis on transgenic mouse
6
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Figure 5. Effects of Ctsg-PML-RARA on multi-lineage hematopoiesis. A. Effects on myeloid and lymphoid lineage hematopoiesis. Bone marrow
cells from indicated mice at 6 weeks of age were mixed at ratios of 1:1, 9:1, or 1:9 with competitor CD45.1+/CD45.2+ bone marrow cells from sex- and
age-matched mice. These cells were transplanted into sex-matched, 6-week-old, lethally irradiated CD45.1+ recipients. At the indicated time points,
peripheral blood was assessed for ratios of CD45.2+ and CD45.1+/CD45.2+ white blood cells within the B220+, CD3+, or Gr1+ compartments. One
sample, two-tailed t-test compared outcomes with the expected values of 10%, 50%, or 90%. Alpha was set at 0.05. Time points with p,0.01 (*) and
p,0.05 ({) are indicated. B–C. Effect of Ctsg-PML-RARA on erythroid lineage hematopoiesis. Bone marrow cells from 6-week-old and 8-week-old,
healthy mice were plated in methylcellulose containing erythropoietin. B. Total colonies after one week in culture (each data point represents results
from an individual mouse in three combined experiments). Results of paired t-test between WT and mCG-PR samples are shown (p-value = 0.002). C.
After one week in culture, total colony cells were washed and the number of immature erythrocytes (cKit+CD71dim) was assessed. Results of a paired
t-test between WT and mCG-PR samples are shown (p-value = 0.007).
doi:10.1371/journal.pone.0046529.g005

genic mouse model of APL. Here we show the transcriptional and
functional consequences of PML-RARA expression in Ctsg-PMLRARA pre-leukemic cells. These findings are not mutually
exclusive, since the hematopoietic compartment susceptible to
PML-RARA transformation may not be at the same developmental
stage as the resultant leukemia [9].
Our work clarifies and expands the findings of Wojiski et al. [8]
Using semi-quantitative RT-PCR, they observed PML-RARA

models because interpretation of viral-transduction models is
complicated both by the heterogeneity of the bone marrow cells
transduced, and by the toxicity of PML-RARA, which is variable
among cell types [28,32,33].
Importantly, this work addresses a different question than the
work of Guibal et al., which defined the immunophenotype of a
committed myeloid progenitor (cKit+CD34+FccRII/III+Ly6gint)
as the leukemia-initiating cell in the hMRP8-PML-RARA transPLOS ONE | www.plosone.org
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Figure 6. Effects of Ctsg-PML-RARA on flow-sorted promyelocytes. A. Experimental schema. Bone marrow cells from Ctsg-PML-RARA and
littermate WT controls were harvested and KLS and promyelocytes were purified by flow sorting. Aliquots from individual donor mice were plated in
methylcellulose containing myeloid cytokines (SCF, IL-3, IL-6, Epo). KLS cells were combined from all donors by genotype and 3,000 cells/recipient
were transferred to sub-lethally irradiated Ly5.1 mice (4 recipients per genotype). Purified promyelocytes were separated into two pools, and 50,000
cells/recipient were transferred into sub-lethally irradiated Ly5.1 mice. B. Total CFUs per 10,000 KLS cells plated by week. Every 7 days, total colonies
were counted. Total cells were then collected in warm (37u) media and serially replated. C. Total CFUs per 10,000 promyelocytes plated by week. D.
Percentage of donor CD45.2+ cells in total bone marrow cells of individual recipient mice 12 weeks after engraftment, with indicated flow sorted cells.
All mice that received promyelocytes had ,1% CD45.2+ cells. E. Percentage of CD45.2+ cells within the Gr1+, CD3+, and CD19+ bone marrow cells of
mice engrafted with promyelocytes.
doi:10.1371/journal.pone.0046529.g006

to lead to long-term engraftment of myeloid restricted cells. Our
data therefore do not support the idea that the promyelocytes from
Ctsg-PML-RARA mice have altered self-renewal properties that
contribute to the expansion of these cells in vivo.
There are no standard immunophenotypic markers for defining
murine promyelocytes, and our flow-sorting strategy for promyelocytes was different than that used by Wojiski et al.; however, we
extensively validated our approach using both expression data
from genes known to be developmentally-regulated during
myeloid development as well as traditional cytomorphology, in
which a trained hematopathologist performed blinded differentials
(Figure S1) [8,34]. Using these techniques, we demonstrate that we
have greatly enriched murine promyelocytes using our flow-sorting

expression in the KLS cells of Ctsg-PML-RARA mice. Their
functional studies revealed increased myeloid self-renewal in flowsorted KLS, CMP, and GMP cells from Ctsg-PML-RARA mice.
They used a PCR-based protocol to demonstrate long-term
engraftment of flow-sorted Ctsg-PML-RARA promyelocytes (Lin2Sca2Ly6g+cKit+CD34+ cells) in sub-lethally irradiated recipient
B6 mice. However, this strategy does not determine whether the
engrafted cells are myeloid-restricted (i.e. derived from promyelocytes) or whether they are multi-lineage (i.e. arising from stem/
progenitor cells that contaminated the purified ‘‘promyelocytes’’).
In contrast, we used Ly5.1 mice as the recipients for our purified
promyelocyte populations, and found that even large numbers of
promyelocytes (50,000 purified cells per recipient) were insufficient
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strategy; however, it remains possible that the different strategy
used by Wojiski et al. enriches for an earlier myeloid population
that could account for the different results regarding ‘‘promyelocyte’’ self-renewal between our studies.
Nonetheless, our data demonstrate that in healthy, pre-leukemic
Ctsg-PML-RARA mice, PML-RARA is first expressed in very early
hematopoietic stem/[progenitor cells (KLS cells), and that its
expression continues throughout myeloid development (CMPs,
GMPs, promyelocytes, and neutrophils). Biological effects of PMLRARA can be seen in pre-leukemic KLS cells, CMPs and GMPs.
Thus, in this model system, it is highly likely that PML-RARA
initiates leukemia in very early hematopoietic cells, and not in
promyelocytes, as originally predicted. Although we cannot
formally exclude the possibility that pre-leukemic promyelocytes
acquire self-renewal properties, it seems very unlikely, based on
recent data that some human APL cells have TCR rearrangements, and express T lineage genes [14]. We suggest that the CtsgPML-RARA mouse model may recapitulate the physiologic timing
of PML-RARA activation in very primitive human HPSCs that are
capable of giving rise to both lymphoid and myeloid cells.
PML-RARA does not appear to alter normal hematopoietic
homeostatic feedback or cause increasing cell numbers within an
immunophenotypically-defined multipotent progenitor compartment (although healthy Ctsg-PML-RARA mice do have a subtle
increase in bone marrow promyelocytes) [2,8,11,24]. Neither we,
nor others, have observed increased numbers of KLS, GMP, CMP
or MEP cells in mouse models of APL [8,20,24,35]. However, we
have identified a competitive advantage in multiple hematopoietic
lineages following transplantation [11], and increased numbers of
myeloid [26,36] and erythroid BFUs in the marrow of Ctsg-PMLRARA mice. Since Ctsg-PML-RARA mice virtually never develop
lymphocytic leukemia or erythroleukemia, our data suggests that
the myeloid restriction of leukemia must be explained by myeloidrestricted genes or proteins that cooperate with PML-RARA in
leukemic cells (Figure 7). Although neutrophil elastase is known to
be one of the critical interacting proteins, further investigation will
be needed to fully define all of the cooperating elements [23,28].

Methods
Mice
Mice expressing PML-RARA from the murine Ctsg locus (CtsgPML-RARA) and Ctsg deficient mice (CG-KO) have been
previously reported [2,37]. The Ctsg-PML-RARA transgenic mice
used in this study were backcrossed more than 12 generations into
the C57Bl/6 Taconic background [38]. The Washington University Animal Studies Committee approved all animal experiments.

Flow Sorting, Expression Array Profiling, and RT-PCR
Validation
Bone marrow cells from individual mice were harvested from
both femurs and tibia of 6-week-old and 13-week-old mice and
prepared previously described [11,24]. Standard red blood cell
lysis was performed with ACK lysis buffer (0.15 M NH4Cl,
10 mM KHC03, 0.1 mM Na2EDTA) on ice for 10 minutes. Nonspecific staining was blocked with Miltenyi FcR Blocking Reagent
for mouse (Auburn, CA). Isotype-matched antibodies were used as
negative controls and the Fluorescence Minus One (FMO) strategy
was used to set appropriate gates. Flow sorting was performed on a
Reflection high-speed cell sorter (i-Cyt, Champaign, IL). Cells
were sorted directly into Trizol (Invitrogen, Carlsbad, CA). Cells
were stained by standard protocols with the following antibodies
(eBioscience unless otherwise noted): KLS (c-Kit+/lineage negative/Sca-1+) cells were assessed using the following lineage
markers: FITC-conjugated aGr-1, aTer119, aCD3, aCD4,
aCD8, aB220, aCD19, and aCD127; APC-ac-Kit, and PEaSca-1. CMPs (Lin2Sca-12cKit+CD34+FccRII/IIIlo), GMPs
(Lin2Sca-12cKit+CD34+FccRII/IIIhi), megakaryocyte-erythrocyte progenitors (MEPs; Lin2Sca-12cKit+CD342FccRII/IIIlo)
were done with the same antibody cocktail as KLS with addition
of APC-conjugated aFccRII/III (clone 93). SLAM (CD150+/
CD412/CD482 KLS) cells were assessed using KLS staining as
above, except for PerCP-Cy5.5–conjugated aSca-1, with the
addition of FITC-aCD41, FITC-aCD48 and PE-aCD150 antibodies. Promyelocyte (Gr1intSCCintB2202CD1152Ter1192) and
neutrophil (Gr1+SCChighB2202CD1152Ter1192) sorting was
done using APC-aGr-1, PE-aCD115, FITC-aB220 and PECy7-aTer119. Additional cells from both the promyelocyte and
neutrophils fraction were sorted into FACS buffer for morphological validation of cytospins. Samples analyzed in expression
array profiling were generated during five separate flow-sorting
experiments to limit technical bias. 15 mouse Ctsg-PML-RARA
leukemia samples were prepared as previously described [38].
For expression array profiling, total cellular RNA was purified
using TRIzol reagent (Invitrogen), quantified using UV spectroscopy (Nanodrop Technologies), and qualitatively assessed using an
Experion Bioanalyzer. Amplified cDNA was prepared from 20 ng
total RNA using the whole transcript WT-Ovation RNA
Amplification System and biotin-labeled using the Encore Biotin
Module, both from NuGen Technologies, according to the
manufacturer’s instructions. Labeled targets were then hybridized
to Mouse Exon 1.0 ST arrays (Affymetrix), washed, stained, and
scanned using standard protocols from the Siteman Cancer
Center, Molecular and Genomic Analysis Core Facility (http://
pathology.wustl.edu/research/cores/lcg/index.php). Affymetrix
Expression Console software was used to process array images,
export signal data, and evaluate image and data quality relative to
standard Affymetrix quality control metrics. Exon array data for
all samples used in this study have been deposited on GEO
(http://www.ncbi.nlm.nih.gov/geo/; SuperSeries accession numbers GSE26131 and GSE40022).

Figure 7. Model of APL development in Ctsg-PML-RARA mice.
Murine APL requires the expression of PML-RARA in a multipotent
progenitor, and cooperation of PML-RARA with myeloid restricted
elements; expression of PML-RARA within promyelocytes is insufficient
to cause leukemia. Orange ellipses indicate compartments with
expression of the indicated genes used to direct expression in
transgenic models. Red arrows indicate inappropriate self-renewal
resulting from Ctsg-PML-RARA expression. Broken arrows indicate that
multiple differentiation steps exist between indicated compartments.
SLAM: lineage negative/Kit+/Sca-1+/CD150+/CD412/CD482. KLS: c-Kit+/
lineage negative/Sca-1+. Pro: promyelocyte. PMN: polymorphic neutrophil. Concept after Lane and Ley [28].
doi:10.1371/journal.pone.0046529.g007
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outcomes with expected values of 10%, 50%, and 90% (Prism,
Graphpad 5, La Jolla, CA). CFU-E analysis was done with a
paired t-test (Excel, Microsoft, Seattle, WA).

For Ctsg qRT-PCR, we performed standard, two-step RT-PCR,
including the Genomic DNA Wipeout step, according to the
manufacturer’s instructions using Ctsg QuantiTect Primers in
conjunction with the QuantiTect SYBER Green RT-PCR Kit
(both from Qiagen, Germantown, Maryland). For PML-RARA
qRT-PCR, we also used the Qiagen RT-PCR kit with the
following primers: Forward TCTTCCTGCCCAACAGCAA,
Reverse GCTTGTAGATGCGGGGTAGAG. We used GAPDH
as the PCR control with the following primers: Forward
TGCACCACCAACTGCTTAG, Reverse GGATGCAGGGATGATGTTC.

Supporting Information
Figure S1 Murine promyelocyte and neutrophil flow
sorting strategy. A. Total bone marrow cells were labeled with
B220, Ter119, CD115 and Gr1 and early myeloid cells/
promyelocytes (Pros) and neutrophils (PMNs) were identified as
B2202, Ter1192, CD1152 cells that are either BSCintGr1int
(Pros), or BSChighGr1high (PMNs). B. Results of 200 cell differential
counts by a blinded hematopathologist from 4 Pros (2 WT and 2
Ctsg-PML-RARA) and 5 PMNs (3 WT and 2 Ctsg-PML-RARA)
separate sorted samples. C. Representative cytomorphology of
WT and Ctsg-PML-RARA (labeled PR) Pros samples counted in B
(1,0006). D. Representative cytomorphology of WT and CtsgPML-RARA (labeled PR) PMNs samples counted in B (1,0006).
(EPS)

Bone marrow Transplantation
Cells used for competitive repopulation studies were injected
retroorbitally, as previously described [11,24]. Two separate
experiments were performed, and the data was combined for
analysis.
Determination of engraftment of flow sorted bone marrow cells
is described in Figure S9. Recipient Ly5.1 mice received either
lethal (1,100 cGy) or sub-lethal (350 cGy) irradiation 24 hours
prior to transplantation with either 16106 total bone marrow cells,
3,000 KLS cells or 50,000 promyelocytes/mouse. At least 20,000
events (peripheral blood) and 40,000 events (bone marrow) per
recipient mouse were collected for analysis.

Figure S2 Validation of Ctsg and PML-RARA expression
using quantitative reverse-transcriptase PCR. A. Ctsg
expression was validated with quantitative RT-PCR normalized to
Gapdh. B. Quantitative RT-PCR using PML-RARA specific primers
normalized to Gapdh in the indicated mice and Nugen amplified
mRNA. C. Agarose gel of PCR products from Panel B. PML-RARA
expected size is 145 bp. Markers are 100 and 200 base-pairs.
(EPS)

Hematopoietic Progenitor Assays
Bone marrow cells from 6-week-old and 8-week-old, healthy
Ctsg-PML-RARA mice and littermate controls were collected and
plated (in duplicate) in 1.1 ml of methylcellulose medium at
41.56103 cells/ml (MethoCult M3334, StemCell Technologies,
Vancouver, Canada) or 8.36103/ml (MethoCult 3434) [37].
Colonies with .30 cells were counted on day 7. Colonies were
collected in 37u DMEM and assessed by flow cytometry using the
following antibodies and FACS Scan (Beckman-Dickenson,
Franklin Lakes, NJ): FITC-aTer119 (BD Pharmingen, Franklin
Lakes, NJ, Ly-76), PE-aCD71 (eBioscience, R17217), PE-aCD11b
(eBioscience, M1/70), and APC-acKit (eBioscience, 2B8), or
serially replated.

Figure S3 Expression of Ly6g, Kit, Flt3 and Cd34 in flow-

sorted bone marrow cells and mouse leukemia samples.
Expression profile in indicated WT and Ctsg-PML-RARA (labeled
mCG-PR) flow-sorted bone marrow cells and 15 Ctsg-PML-RARA
leukemia samples (labeled Mouse APL) using Nugen amplified
mRNA and Affymetrix Mouse Exon 1.0ST arrays. We plotted
Ly6g, Kit, Flt3 and Cd34 expression using representative probesets.
(EPS)
Figure S4 Expression of 7 developmentally-regulated
myeloid genes in flow-sorted bone marrow cells.
Expression profile in indicated WT and Ctsg-PML-RARA (labeled
mCG-PR) flow-sorted bone marrow cells and 15 Ctsg-PML-RARA
leukemia samples (labeled Mouse APL) using Nugen amplified
mRNA and Affymetrix Mouse Exon 1.0ST arrays. We plotted
Elane, Prtn3, Mpo, Ltf, Mmp9, Lyz2, and Fpr1 expression using
representative probesets.
(EPS)

Statistical analysis
Expression array analysis: exon-level summary was generated
using the RMA algorithm in the Affymetrix Expression Console
(Affymetrix Inc., USA). Only core probesets were used in order to
limit the analysis within well-annotated exons with the exception
of Ly6g, whose 2 probesets are within the extended probesets
group. Probesets having an expression signal less than 200 in all
samples were removed and an unsupervised hierarchical clustering
analysis was performed using z-score normalized expression values
in SPOTFIRE (Decision Site version 9.1.1, Somerville, USA) or
with the Partek Genomics Suite (Saint Louis, MO) with the
expression of each gene standardized to a mean of 0 and standard
deviation of 1 and using the Pearson dissimilarity as a distance
measure. Results did not segregate based on age of the mice used
in this analysis (6-week-old vs 13-week-old), and so the data were
combined. Supervised clustering analyses were done using SPOTFIRE as described in the text. Comparison of cell populations
using ANOVA was done with Partek with fold change $2 and
unadjusted p-values as noted in the text. Comparisons of cell
populations using SAM Version 4.0 (http://www-stat.stanford.
edu/,tibs/SAM/, Palo Alto, CA) as an Excel add-in performing
two-class unpaired analyses with unlogged data, 100 permutations,
standard regression and fold change $2 with false discovery rates
and q-values noted in the text. Competitive repopulation analysis:
a one sample, two-tailed t-test with alpha set at 0.05 compared
PLOS ONE | www.plosone.org

Expression profile of flow-sorted Ctsg-PMLRARA and WT bone marrow cells by unsupervised
clustering analyses. Bone marrow cells were flow sorted as
described in Figure 1, and analyzed using Affymetrix Exon 1.0ST
arrays. A: Unsupervised hierarchal clustering using SPOTFIRE of
expression array data from flow-sorted SLAM and KLS cells from
littermate 6-week-old and 13-week-old healthy WT (2/2) vs.
mCG-PR mice (+/2). Clustering occurs by genotype within the
KLS samples, but not the SLAM samples. Samples were
generated during two independent flow-sorting experiments to
minimize technical bias. B. Unsupervised hierarchal clustering
using SPOTFIRE of expression array data of flow-sorted
promyelocytes cells from littermate 8-week-old healthy WT (2/
2) vs. mCG-PR mice (+/2). Clusters do not segregate by
genotype. Samples were generated with three independent flowsorting experiments to minimize technical bias. The legend is
shown below the heatmaps with downregulated genes in green and
upregulated genes in red.
(EPS)

Figure S5
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Unsupervised heatmap clustering analyses
for WT vs. Ctsg-PML-RARA CMP, GMP and MEP
samples. Bone marrow cells were flow sorted as described in
the Methods section, and analyzed using Affymetrix Exon 1.0ST
arrays. An unsupervised clustering analysis was performed using
Partek with Pearson dissimilarity as the distance measure.
Probesets with signal intensity of less than 200 in all samples were
removed from the analyses. The legend is shown below each
heatmap with downregulated genes in green and upregulated
genes in red. A. Unsupervised heatmap clustering analyses for
CMP WT vs. Ctsg-PML-RARA samples. B. Unsupervised heatmap
clustering analyses for GMP WT vs. Ctsg-PML-RARA samples. C.
Unsupervised heatmap clustering analyses for MEP WT vs. CtsgPML-RARA samples.
(EPS)

mRNA abundance identified in primary human APL samples
[39,40].
(DOCX)

Figure S6

Table S1 Ctsg-PML-RARA versus WT SLAM ANOVA

Results.
(XLSX)
Table S2 Ctsg-PML-RARA versus WT KLS ANOVA

Results.
(XLSX)
Table S3 Ctsg-PML-RARA versus WT CMP ANOVA

Results.
(XLSX)
Table S4 Ctsg-PML-RARA versus WT GMP ANOVA

Results.
(XLSX)

Figure S7 Individual supervised clustering analyses for

the significantly dysregulated genes by ANOVA from the
GMP and CMP comparisons between WT and CtsgPML-RARA samples. These heatmaps were created by
traditional z-score scaling using SPOTFIRE. The clustering with
genes dysregulated in either the CMP or GMP compartment by
ANOVA (with unadjusted p value,0.001, fold change $2)
segregated both the GMP and CMP populations, but not the
MEP populations, by genotype. The legend is shown below the
heatmaps with downregulated genes in green and upregulated
genes in red. A. Supervised clustering heatmap using genes
dysregulated by ANOVA comparison between WT and Ctsg-PMLRARA CMP populations. B. Supervised clustering heatmap using
genes dysregulated by ANOVA comparison between WT and
Ctsg-PML-RARA GMP populations.
(EPS)

Table S5

Table S6 Ctsg-PML-RARA versus WT Promyelocyte
ANOVA Results.
(XLSX)
Table S7 Concordant Dysregulated Genes in both the
CMP and GMP Compartments by ANOVA.
(XLSX)
Table S8 Ctsg-PML-RARA versus WT SLAM SAM Re-

sults.
(XLSX)
Table S9 Ctsg-PML-RARA versus WT KLS SAM Results.

Erythroid colony formation (CFU-E) in CtsgPML-RARA vs. WT mice. Bone marrow cells from 6-week-old
and 8-week-old, healthy mice were plated in methylcellulose
containing erythropoietin (Methocult 3334). Results of paired ttests are shown in each panel. A. Immunophenotypes of cells in
these colonies were assessed as indicated: A. Ter119+CD71high
(mature erythrocytes) and B. CD11b+ (myelomonocytic/monocytic cells). C. and D. Hemoglobin and mean corpuscular volume
(MCV) values were determined in a cohort of healthy 4-month-old
mice with the indicated genotypes.
(EPS)
Figure S8

(XLSX)
Table S10

Ctsg-PML-RARA versus WT CMP SAM Re-

sults.
(XLSX)
Table S11

Ctsg-PML-RARA versus WT GMP SAM Re-

sults.
(XLSX)
Table S12

Ctsg-PML-RARA versus WT MEP SAM Re-

sults.
(XLSX)

Figure S9 Examples of bone marrow immunophenotypes following transplantation of flow sorted KLS and
promyelocytes. Bone marrow KLS and promyelocytes were
sorted from littermate Ctsg-PML-RARA (mCG-PR) and WT mice
and transplanted into sub-lethally irradiated Ly5.1 recipients
(Figure 6). Twelve weeks after transplantation, bone marrow cells
were harvested and assessed for Gr1, CD3, CD19, CD45.2 and
CD45.1 expression. At least 40,000 events were collected per
recipient. A–C. Representative recipient of KLS transplantation.
D–F. Representative recipient of promyelocyte transplantation.
(EPS)

Table S13 Ctsg-PML-RARA versus WT Promyelocyte
SAM Results.
(XLSX)
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